Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 28

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Phospholamban pentamerization increases sensitivity and dynamic range of cardiac relaxation

Funk, Florian, Kronenbitter, Annette, Hackert, Katarzyna, Oebbeke, Matthias, Klebe, Gerhard, Barth, Mareike, Koch, Daniel, Schmitt, Joachim P · 2023 · Cardiovascular Research

Abstract

Aims: A key event in the regulation of cardiac contraction and relaxation is the phosphorylation of phospholamban (PLN) that relieves the inhibition of the sarco/endoplasmic reticulum (SR) Ca2+-ATPase (SERCA2a). PLN exists in an equilibrium between monomers and pentamers. While only monomers can inhibit SERCA2a by direct interaction, the functional role of pentamers is still unclear. This study investigates the functional consequences of PLN pentamerization. Methods and results: We generated transgenic mouse models expressing either a PLN mutant that cannot form pentamers (TgAFA-PLN) or wild-type PLN (TgPLN) in a PLN-deficient background. TgAFA-PLN hearts demonstrated three-fold stronger phosphorylation of monomeric PLN, accelerated Ca2+ cycling of cardiomyocytes, and enhanced contraction and relaxation of sarcomeres and whole hearts in vivo. All of these effects were observed under baseline conditions and abrogated upon inhibition of protein kinase A (PKA). Mechanistically, far western kinase assays revealed that PLN pentamers are phosphorylated by PKA directly and independent of any subunit exchange for free monomers. In vitro phosphorylation of synthetic PLN demonstrated that pentamers even provide a preferred PKA substrate and compete with monomers for the kinase, thereby reducing monomer phosphorylation and maximizing SERCA2a inhibition. However, β-adrenergic stimulation induced strong PLN monomer phosphorylation in TgPLN hearts and sharp acceleration of cardiomyocyte Ca2+ cycling and haemodynamic values that now were indistinguishable from TgAFA-PLN and PLN-KO hearts. The pathophysiological relevance of PLN pentamerization was evaluated using transverse aortic constriction (TAC) to induce left ventricular pressure overload. Compared to TgPLN, TgAFA-PLN mice demonstrated reduced survival after TAC, impaired cardiac haemodynamics, failure to respond to adrenergic stimulation, higher heart weight, and increased myocardial fibrosis. Conclusions: The findings show that PLN pentamerization greatly impacts on SERCA2a activity as it mediates the full range of PLN effects from maximum inhibition to full release of SERCA2a function. This regulation is important for myocardial adaptation to sustained pressure overload.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cvr/cvad037

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 56

  1. Bers, 2000, Calcium fluxes involved in control of cardiac myocyte contraction, Circ Res, 87, 275, 10.1161/01.RES.87.4.275 · DOI · Paper page
  2. Mattiazzi, 2005, Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions, Cardiovasc Res, 68, 366, 10.1016/j.cardiores.2005.08.010 · DOI · Paper page
  3. Cornea, 1997, Mutation and phosphorylation change the oligomeric structure of phospholamban in lipid bilayers, Biochemistry, 36, 2960, 10.1021/bi961955q · DOI · Paper page
  4. Simmerman, 1996, A leucine zipper stabilizes the pentameric membrane domain of phospholamban and forms a coiled-coil pore structure, J Biol Chem, 271, 5941, 10.1074/jbc.271.10.5941 · DOI · Paper page
  5. Kimura, 1997, Phospholamban inhibitory function is activated by depolymerization, J Biol Chem, 272, 15061, 10.1074/jbc.272.24.15061 · DOI · Paper page
  6. Zvaritch, 2000, The transgenic expression of highly inhibitory monomeric forms of phospholamban in mouse heart impairs cardiac contractility, J Biol Chem, 275, 14985, 10.1074/jbc.275.20.14985 · DOI
  7. Autry, 1997, Functional co-expression of the canine cardiac Ca2+pump and phospholamban in spodoptera frugiperda (Sf21) cells reveals new insights on ATPase regulation, J Biol Chem, 272, 15872, 10.1074/jbc.272.25.15872 · DOI · Paper page
  8. MacLennan, 1997, Sites of regulatory interaction between calcium ATPases and phospholamban, Basic ResCardiol, 92, 11, 10.1007/BF00794063 · doi:10.1007/bf00794063
  9. Hou, 2008, Phosphomimetic mutations increase phospholamban oligomerization and alter the structure of its regulatory complex, J Biol Chem, 283, 28996, 10.1074/jbc.M804782200 · doi:10.1074/jbc.m804782200
  10. Glaves, 2011, Phosphorylation and mutation of phospholamban alter physical interactions with the sarcoplasmic reticulum calcium pump, J Mol Biol, 405, 707, 10.1016/j.jmb.2010.11.014 · DOI
  11. Stokes, 2006, Interactions between Ca2+-ATPase and the pentameric form of phospholamban in two-dimensional co-crystals, Biophys J, 90, 4213, 10.1529/biophysj.105.079640 · doi:10.1529/biophysj.105.079640
  12. Glaves, 2019, The phospholamban pentamer alters function of the sarcoplasmic Reticulum calcium pump SERCA, Biophys J, 116, 633, 10.1016/j.bpj.2019.01.013 · DOI
  13. Ceholski, 2012, Lethal, hereditary mutants of phospholamban elude phosphorylation by protein kinase A, J Biol Chem, 287, 26596, 10.1074/jbc.M112.382713 · DOI · Paper page
  14. Wittmann, 2015, Phospholamban pentamers attenuate PKA-dependent phosphorylation of monomers, J Mol Cell Cardiol, 80, 90, 10.1016/j.yjmcc.2014.12.020 · doi:10.1016/j.yjmcc.2014.12.020
  15. Koch, 2021, Molecular noise filtering in the β-adrenergic signaling network by phospholamban pentamers, Cell Rep, 36, 109448, 10.1016/j.celrep.2021.109448 · DOI
  16. Schmitt, 2003, Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban, Science, 299, 1410, 10.1126/science.1081578 · DOI · Paper page
  17. Schmid, 2015, Cardiac RKIP induces a beneficial β-adrenoceptor–dependent positive inotropy, Nat Med, 21, 1298, 10.1038/nm.3972 · DOI · Paper page
  18. Haghighi, 2012, The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase, J Mol Cell Cardiol, 52, 773, 10.1016/j.yjmcc.2011.11.012 · DOI
  19. Schmitt, 2003, Consequences of pressure overload on sarcomere protein mutation-induced hypertrophic cardiomyopathy, Circulation, 108, 1133, 10.1161/01.CIR.0000086469.85750.48 · doi:10.1161/01.cir.0000086469.85750.48
  20. Lorenz, 2008, A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy, Nat Med, 15, 75, 10.1038/nm.1893 · DOI · Paper page
  21. Blankenburg, 2014, β-Myosin heavy chain variant Val606Met causes very mild hypertrophic cardiomyopathy in mice, but exacerbates HCM phenotypes in mice carrying other HCM mutations, Circ Res, 115, 227, 10.1161/CIRCRESAHA.115.303178 · DOI
  22. Schmitt, 2009, Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition, Circulation, 119, 436, 10.1161/CIRCULATIONAHA.108.783506 · DOI
  23. Wu, 2007, Detecting protein–protein interactions by far western blotting, Nat Protoc, 2, 3278, 10.1038/nprot.2007.459 · DOI · Paper page
  24. Robia, 2007, Förster transfer recovery reveals that phospholamban exchanges slowly from pentamers but rapidly from the SERCA regulatory complex, Circ Res, 101, 1123, 10.1161/CIRCRESAHA.107.159947 · doi:10.1161/circresaha.107.159947
  25. Karim, 2000, Synthetic null-cysteine phospholamban analogue and the corresponding transmembrane domain inhibit the Ca-ATPase, Biochemistry, 39, 10892, 10.1021/bi0003543 · DOI
  26. Verardi, 2011, Structural topology of phospholamban pentamer in lipid bilayers by a hybrid solution and solid-state NMR method, Proc Natl Acad Sci, 108, 9101, 10.1073/pnas.1016535108 · DOI · Paper page
  27. Gustavsson, 2013, Allosteric regulation of SERCA by phosphorylation-mediated conformational shift of phospholamban, Proc Natl Acad Sci, 110, 17338, 10.1073/pnas.1303006110 · DOI · Paper page
  28. MacLennan, 2003, Phospholamban: a crucial regulator of cardiac contractility, Nat Rev Mol Cell Biol, 4, 566, 10.1038/nrm1151 · DOI · Paper page
  29. Schellenberger, 2002, Analysis of enzyme specificity by multiple substrate kinetics, Biochemistry, 32, 4344, 10.1021/bi00067a025 · doi:10.1021/bi00067a025
  30. Anderson, 2015, Multiple alternative substrate kinetics, Biochim Biophys Acta, 1854, 1729, 10.1016/j.bbapap.2015.05.016 · doi:10.1016/j.bbapap.2015.05.016
  31. Luo, 1994, Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation, Circ Res, 75, 401, 10.1161/01.RES.75.3.401 · DOI · Paper page
  32. Akin, 2013, The structural basis for phospholamban inhibition of the calcium pump in sarcoplasmic reticulum, J Biol Chem, 288, 30181, 10.1074/jbc.M113.501585 · DOI · Paper page
  33. Asahi, 2002, Sarcolipin inhibits polymerization of phospholamban to induce superinhibition of sarco(endo)plasmic reticulum Ca2+-ATPases (SERCAs), J Biol Chem, 277, 26725, 10.1074/jbc.C200269200 · DOI
  34. Chu, 1998, Pentameric assembly of phospholamban facilitates inhibition of cardiac function in vivo, J Biol Chem, 273, 33674, 10.1074/jbc.273.50.33674 · doi:10.1074/jbc.273.50.33674
  35. Menzel, 2020, 14-3-3 Binding creates a memory of kinase action by stabilizing the modified state of phospholamban, Sci Signal, 13, eaaz1436, 10.1126/scisignal.aaz1436 · DOI · Paper page
  36. Li, 1990, Immunological detection of phospholamban phosphorylation states facilitates the description of the mechanism of phosphorylation and dephosphorylation, Biochemistry, 29, 4535, 10.1021/bi00471a005 · DOI
  37. Jackson, 1996, Translation of Ser16 and Thr17 phosphorylation of phospholamban into Ca2+-pump stimulation, Biochem J, 316, 201, 10.1042/bj3160201 · DOI
  38. Fisher, 2021, Dwarf open reading frame (DWORF) is a direct activator of the sarcoplasmic reticulum calcium pump SERCA, Elife, 10, e65545, 10.7554/eLife.65545 · DOI
  39. Kiewitz, 2003, Ca2+-dependent interaction of S100A1 with the sarcoplasmic reticulum Ca2+-ATPase2a and phospholamban in the human heart, Biochem Biophys Res Commun, 306, 550, 10.1016/S0006-291X(03)00987-2 · DOI
  40. Eisner, 2013, Sarcoplasmic reticulum Ca-ATPase and heart failure 20 years later, Circ Res, 113, 958, 10.1161/CIRCRESAHA.113.302187 · DOI
  41. Kho, 2012, Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapy, Nat Rev Cardiol, 9, 717, 10.1038/nrcardio.2012.145 · DOI · Paper page
  42. Kaye, 2007, Percutaneous cardiac recirculation-mediated gene transfer of an inhibitory phospholamban peptide reverses advanced heart failure in large animals, J Am Coll Cardiol, 50, 253, 10.1016/j.jacc.2007.03.047 · DOI · Paper page
  43. Tsuji, 2009, Rescue of Ca2+overload-induced left ventricular dysfunction by targeted ablation of phospholamban, Am J Physiol Hear Circ Physiol, 296, 310, 10.1152/ajpheart.00975.2008 · doi:10.1152/ajpheart.00975.2008
  44. Dieterle, 2005, Gene transfer of a phospholamban-targeted antibody improves calcium handling and cardiac function in heart failure, Cardiovasc Res, 67, 678, 10.1016/j.cardiores.2005.04.029 · DOI
  45. Del Monte, 2002, Targeting phospholamban by gene transfer in human heart failure, Circulation, 105, 904, 10.1161/hc0802.105564 · DOI · Paper page
  46. Suckau, 2009, Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy, Circulation, 119, 1241, 10.1161/CIRCULATIONAHA.108.783852 · DOI · Paper page
  47. Beverborg, 2021, Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy, Nat Commun, 12, 1
  48. Nicolaou, 2009, Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury, Circ Res, 104, 1012, 10.1161/CIRCRESAHA.108.189811 · DOI
  49. Jessup, 2011, Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure, Circulation, 124, 304, 10.1161/CIRCULATIONAHA.111.022889 · DOI · Paper page
  50. Haghighi, 2006, A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy, Proc Natl Acad Sci U S A, 103, 1388, 10.1073/pnas.0510519103 · DOI · Paper page
  51. Ha, 2011, Lethal Arg9Cys phospholamban mutation hinders Ca2+-ATPase regulation and phosphorylation by protein kinase A, Proc Natl Acad Sci U S A, 108, 2735, 10.1073/pnas.1013987108 · DOI
  52. Mørk, 2007, Increased cardiomyocyte function and Ca2+transients in mice during early congestive heart failure, J Mol Cell Cardiol, 43, 177, 10.1016/j.yjmcc.2007.05.004 · DOI
  53. Kiss, 1995, Differential changes in cardiac phospholamban and sarcoplasmic reticular Ca2+-ATPase protein levels, Circ Res, 77, 759, 10.1161/01.RES.77.4.759 · DOI · Paper page
  54. Jiang, 1993, Age-related alterations in the phosphorylation of sarcoplasmic reticulum and myofibrillar proteins and diminished contractile response to isoproterenol in intact rat ventricle, Circ Res, 72, 102, 10.1161/01.RES.72.1.102 · DOI
  55. Gergs, 2019, Alterations of protein expression of phospholamban, ZASP and plakoglobin in human atria in subgroups of seniors, Sci Rep, 9, 1, 10.1038/s41598-019-42141-w · DOI
  56. Reddy, 1999, Depolymerization of phospholamban in the presence of calcium pump: a fluorescence energy transfer study, Biochemistry, 38, 3954, 10.1021/bi981795d · DOI · Paper page

Cited by

See all 28

Metadata

Authors
Funk, F., Kronenbitter, A., Hackert, K., Oebbeke, M., Klebe, G., Barth, M., Koch, D., & Schmitt, J. P.
Affiliations
  • Institute of Pharmacology, University Hospital Düsseldorf, and Cardiovascular Research Institute Düsseldorf (CARID), Heinrich-Heine-University , Universitätsstraße 1, 40225 Düsseldorf , Germany
  • Institute of Pharmaceutical Chemistry, Philipps-University Marburg , Marbacher Weg 6, 35032 Marburg , Germany
  • Department of Cardiovascular Surgery, University Hospital Düsseldorf, Heinrich-Heine-University , Moorenstr. 5, 40225 Düsseldorf , Germany
  • Max Planck Institute for Neurobiology of Behavior—caesar, Cellular computations and learning group , Ludwig-Erhard-Allee 2, 53175 Bonn , Germany
Venue
Cardiovascular Research
Published
2023-03-03
Volume
119
Issue
7
Pages
1568-1582
ISSN
  • 0008-6363
  • 1755-3245
Cited by
28
References
3
Language
en
Funders
  • Deutsche Forschungsgemeinschaft
  • German Research Foundation (236177352- SFB 1116, TPA02 to J.P.S, SCHM1493/4-1 to J.P.S)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phospholamban pentamerization increases sensitivity and dynamic range of cardiac relaxation. https://app.cochat.ai/papers/10.1093/cvr/cvad037
The paper
Funk, F., Kronenbitter, A., Hackert, K., Oebbeke, M., Klebe, G., Barth, M., Koch, D., & Schmitt, J. P. (2023). Phospholamban pentamerization increases sensitivity and dynamic range of cardiac relaxation. Cardiovascular Research. https://doi.org/10.1093/cvr/cvad037

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.